Foster Victor Wealth Advisors LLC Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Foster Victor Wealth Advisors LLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 115.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,719 shares of the life sciences company’s stock after purchasing an additional 4,143 shares during the period. Illumina makes up approximately 1.3% of Foster Victor Wealth Advisors LLC’s holdings, making the stock its 22nd largest position. Foster Victor Wealth Advisors LLC’s holdings in Illumina were worth $2,328,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Clarus Wealth Advisors purchased a new position in shares of Illumina during the third quarter valued at approximately $304,000. Intellectus Partners LLC lifted its holdings in shares of Illumina by 1.4% during the third quarter. Intellectus Partners LLC now owns 7,960 shares of the life sciences company’s stock valued at $2,422,000 after purchasing an additional 109 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Illumina by 11.4% during the third quarter. Pacer Advisors Inc. now owns 26,424 shares of the life sciences company’s stock valued at $8,039,000 after purchasing an additional 2,706 shares during the last quarter. Quattro Financial Advisors LLC purchased a new position in shares of Illumina during the third quarter valued at approximately $1,687,000. Finally, Gofen & Glossberg LLC IL lifted its holdings in shares of Illumina by 6.8% during the third quarter. Gofen & Glossberg LLC IL now owns 787 shares of the life sciences company’s stock valued at $239,000 after purchasing an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 90.90% of the company’s stock.

NASDAQ ILMN traded up $5.07 during mid-day trading on Friday, reaching $303.25. The stock had a trading volume of 49,755 shares, compared to its average volume of 1,028,585. Illumina, Inc. has a 1 year low of $263.30 and a 1 year high of $380.76. The stock has a market cap of $42.39 billion, a PE ratio of 53.02, a price-to-earnings-growth ratio of 2.87 and a beta of 1.07. The company has a fifty day moving average price of $291.13 and a 200 day moving average price of $312.97. The company has a debt-to-equity ratio of 0.42, a current ratio of 6.79 and a quick ratio of 6.10.



Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The company had revenue of $838.00 million during the quarter, compared to analyst estimates of $835.12 million. During the same period in the previous year, the business earned $1.43 EPS. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. As a group, equities research analysts expect that Illumina, Inc. will post 6.04 earnings per share for the current year.

In other Illumina news, CEO Francis A. Desouza sold 3,000 shares of Illumina stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $301.25, for a total value of $903,750.00. Following the completion of the sale, the chief executive officer now owns 64,200 shares of the company’s stock, valued at approximately $19,340,250. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $302.04, for a total transaction of $3,020,400.00. Following the completion of the sale, the senior vice president now directly owns 86,776 shares of the company’s stock, valued at approximately $26,209,823.04. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,099 shares of company stock valued at $13,897,460. 0.38% of the stock is owned by company insiders.

Several equities analysts have recently issued reports on ILMN shares. Deutsche Bank lowered their target price on shares of Illumina from $290.00 to $280.00 and set a “hold” rating for the company in a report on Friday, July 12th. Argus lifted their target price on shares of Illumina from $300.00 to $340.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. UBS Group lifted their target price on shares of Illumina from $350.00 to $355.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. Credit Suisse Group reiterated a “buy” rating and set a $340.00 target price on shares of Illumina in a report on Wednesday, July 31st. Finally, BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a report on Friday, September 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company’s stock. Illumina presently has a consensus rating of “Buy” and a consensus target price of $330.92.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

See Also: Street Name

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.